Skip to content

Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia

The Mechanism of Non-invasive Brain Stimulation for Therapy of Chronic Auditory Verbal Hallucinations in Schizophrenia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01801787
Enrollment
30
Registered
2013-03-01
Start date
2013-03-31
Completion date
2015-12-31
Last updated
2016-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Auditory Verbal Hallucinations, Schizophrenia

Brief summary

The current study investigates the basic principles that underlie the efficacy of transcranial direct current stimulation for chronic auditory verbal hallucinations in schizophrenia in a multimodal design.

Interventions

DEVICEtDCS

active vs. sham tDCS left hemisphere

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of schizophrenia * chronic auditory verbal hallucinations * right-handed

Exclusion criteria

* drug abuse other than nicotine * severe cognitive deficits * severe medical conditions * severe neurological disorders * severe microangiopathy * history of electroconvulsive therapy * pregnancy or lactation

Design outcomes

Primary

MeasureTime frameDescription
Change of Auditory Hallucination Rating Scale scorebaseline; 3 days after intervention; 3 months after interventionAuditory Hallucination Rating Scale score will be assessed at baseline; changes thereof at 3 days after intervention and 3 months after intervention are primary outcome measures

Secondary

MeasureTime frameDescription
Positive And Negative Syndrome Scalebaseline; 3 days after intervention; 3 months after interventionPositive And Negative Syndrome Scale score will be assessed at baseline; changes thereof at 3 days after intervention and 3 months after intervention are secondary outcome measures

Other

MeasureTime frameDescription
N1 suppression during talking and listeningbaseline; 3 days after interventionN1 suppression during talking and listening will be assessed at baseline; change thereof at 3 days after intervention is further outcome measure
Diffusion Tensor Imaging: Fractional anisotropy of longitudinal superior fascicle and arcuate fasciclebaseline; 3 days after interventionFractional anisotropy of longitudinal superior fascicle and arcuate fascicle will be assessed at baseline; change thereof 3 days after intervention is further outcome measure
Default Mode Network connectivitybaseline; 3 days after interventionDefault Mode Network connectivity will be assessed at baseline; change thereof 3 days after intervention is further outcome measure

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026